|
NR-2632
|
Polyclonal Anti-Vaccinia Virus (immune globulin G, Human)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-417
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-2), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-418
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-3), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-419
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-4), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-420
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-5), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-421
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-6), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-422
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-7)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-423
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-8)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-424
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-9)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-426
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-11)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-427
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-12)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-428
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-13)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-429
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-14)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-430
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-15)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-431
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-16)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-4546
|
Monoclonal Anti-Adenovirus E19, Clone TW1.3 (produced in vitro)
|
Adenovirus
|
BEI Level 1
|
|
NR-4547
|
Monoclonal Anti-Vaccinia Virus E3L, Clone TW2.3 (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-551
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-20)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-552
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-21)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-553
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-22)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-554
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-23)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-555
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-24)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-556
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-25)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-559
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-28)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-560
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-29)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-561
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-30)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-562
|
Monoclonal Anti-Vaccinia (WR) B5R, Residues 20 to 275, Ectodomain (similar to VMC-31)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-565
|
Monoclonal Anti-Vaccinia (WR) A33R, Residues 58 to 185 (similar to VMC-34)(produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-566
|
Monoclonal Anti-Vaccinia (WR) L1R, Residues 1 to 185 (similar to VMC-35), (produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-567
|
Monoclonal Anti-Vaccinia (WR) A27L, Residues 1 to 110 (similar to VMC-38),(produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-568
|
Monoclonal Anti-Vaccinia (WR) A27L, Residues 1 to 110 (similar to VMC-49),(produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-569
|
Monoclonal Anti-Vaccinia (WR) A27L, Residues 1 to 110 (similar to VMC-50),(produced in vitro)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-627
|
Polyclonal Anti-Vaccinia Virus (WR) A27L Protein, (antiserum, Rabbit)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-628
|
Polyclonal Anti-Vaccinia Virus (WR) A33R Protein, (antiserum, Rabbit)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-629
|
Polyclonal Anti-Vaccinia Virus (WR) B5R Protein, (antiserum, Rabbit)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-630
|
Polyclonal Anti-Vaccinia Virus (WR) F9L Protein, (antiserum, Rabbit)
|
Vaccinia virus
|
BEI Level 1
|
|
NR-631
|
Polyclonal Anti-Vaccinia Virus (WR) L1R Protein, (antiserum, Rabbit)
|
Vaccinia virus
|
BEI Level 1
|